FDA revises compliance guide on pre-approval inspections for pharmaceuticals

The U.S. Food and Drug Administration (FDA) has issued a revised compliance guide concerning pre-approval inspections for pharmaceutical manufacturing facilities. This update outlines the agency's current protocols for assessing a facility's capability to manufacture a drug and its compliance with quality standards before a marketing application is approved. For the pharmaceutical sector, these revisions are critical as they dictate the regulatory path for new product approvals and can impact commercialization timelines.